Breast cancer patients die while waiting for medicines demanded at march
Health Select Committee hearings underway, in response to public march to Parliament
Media release
BCAC News
Calling all Metavivors to speak their minds
Metavivors have a tremendous opportunity to tell politicians about your experience with breast cancer and your needs.
Health Select Committee gathering information on drug funding
Parliament’s Health Select Committee has announced that it has “opened a briefing” on PHARMAC funding and patient access to drugs.
Reflecting on a year of achievement
We had a fabulous opportunity to look back at everything we have achieved this year at our AGM in Auckland recently.
Health Select Committee told to review medicines funding
Three people who are fighting to have important medicines funded for women with advanced breast cancer appeared before Parliament’s Health Select Committee hearing on 4 December to strongly put the
Metavivors march on Parliament
It was amazing to see so many wonderful, inspiring women march to Parliament recently to present petitions calling for funding of important medicines for advanced breast cancer.
Powerful march and petition to Parliament: 16 October 2018
Women with breast cancer, their family, whanau and supporters are marching to Parliament on 16 October to present petitions to MPs – calling for the funding of breakthrough advanced breast cancer m
Sharing the latest on Australia & New Zealand breast cancer research
A wealth of knowledge has been brought back to New Zealand by two Breast Cancer Aotearoa Coalition representatives following the Breast Cancer Trials Australia New Zealand annual scientific meeting
Oncologists need a broader range of medicines in New Zealand
Recent international developments in breast cancer medicine approvals emphasise the need for a much broader range of medicines in New Zealand.
Submission to PHARMAC requesting funding of Perjeta for all who need it
Breast Cancer Aotearoa Coalition and Breast Cancer Foundation NZ have made a strongly worded and evidence-based joint submission to PHARMAC requesting that funding for Perjeta (pertuzumab) be exten
